Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia.
Kirschbaum MH, Synold T, Stein AS, Tuscano J, Zain JM, Popplewell L, Karanes C, O'Donnell MR, Pulone B, Rincon A, Wright J, Frankel P, Forman SJ, Newman EM. Kirschbaum MH, et al. Among authors: tuscano j. Leukemia. 2011 Oct;25(10):1543-7. doi: 10.1038/leu.2011.124. Epub 2011 May 31. Leukemia. 2011. PMID: 21625235 Free PMC article. Clinical Trial.
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial.
Somlo G, Lashkari A, Bellamy W, Zimmerman TM, Tuscano JM, O'Donnell MR, Mohrbacher AF, Forman SJ, Frankel P, Chen HX, Doroshow JH, Gandara DR. Somlo G, et al. Among authors: tuscano jm. Br J Haematol. 2011 Aug;154(4):533-5. doi: 10.1111/j.1365-2141.2011.08623.x. Epub 2011 Apr 26. Br J Haematol. 2011. PMID: 21517811 Free PMC article. Clinical Trial. No abstract available.
A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.
Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B, Tuscano JM, Newman EM. Kirschbaum MH, et al. Leuk Lymphoma. 2014 Oct;55(10):2301-4. doi: 10.3109/10428194.2013.877134. Epub 2014 Feb 24. Leuk Lymphoma. 2014. PMID: 24369094 Free PMC article. Clinical Trial.
A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.
Kirschbaum MH, Frankel P, Synold TW, Xie Z, Yen Y, Popplewell L, Chen R, Aljitawi O, Tuscano JM, Chan KK, Newman EM. Kirschbaum MH, et al. Leuk Lymphoma. 2016 Oct;57(10):2307-14. doi: 10.3109/10428194.2016.1146947. Epub 2016 Feb 19. Leuk Lymphoma. 2016. PMID: 26895565 Free PMC article. Clinical Trial.
A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study.
Kirschbaum MH, Frankel P, Synold TW, Zain J, Claxton D, Tuscano J, Newman EM, Gandara DR, Lara PN Jr. Kirschbaum MH, et al. Among authors: tuscano j. Br J Haematol. 2018 Feb;180(3):445-448. doi: 10.1111/bjh.14333. Epub 2016 Sep 21. Br J Haematol. 2018. PMID: 27650362 Free PMC article. Clinical Trial. No abstract available.
A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma.
Tuscano JM, Maverakis E, Groshen S, Tsao-Wei D, Luxardi G, Merleev AA, Beaven A, DiPersio JF, Popplewell L, Chen R, Kirschbaum M, Schroeder MA, Newman EM. Tuscano JM, et al. Clin Cancer Res. 2019 Dec 1;25(23):7004-7013. doi: 10.1158/1078-0432.CCR-19-0438. Epub 2019 Sep 3. Clin Cancer Res. 2019. PMID: 31481504 Free PMC article. Clinical Trial.
Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
Kambhampati S, Fakhri B, Ai WZ, Kaplan LD, Tuscano JM, Wieduwilt MJ, Sudhindra A, Cavallone E, Reiner J, Aoun C, Castillo M, Martinelli M, Ta T, Le D, Padilla M, Crawford E, Andreadis CB. Kambhampati S, et al. Among authors: tuscano jm. Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):139-146. doi: 10.1016/j.clml.2020.12.020. Epub 2020 Dec 24. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33478921 Clinical Trial.
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma.
Chavez JC, Foss FM, William BM, Brammer JE, Smith SM, Prica A, Zain JM, Tuscano JM, Shah H, Mehta-Shah N, Geethakumari PR, Wang BX, Zantinge S, Wang L, Zhang L, Boutrin A, Zhao W, Cheng L, Standifer N, Hewitt L, Enowtambong E, Shao W, Sharma S, Carlesso G, Moscow JA, Siu LL. Chavez JC, et al. Clin Cancer Res. 2023 May 15;29(10):1869-1878. doi: 10.1158/1078-0432.CCR-22-2955. Clin Cancer Res. 2023. PMID: 36826995 Free PMC article.
121 results